2012-02-11 04:04:25 - Recently published research from Global Markets Direct, "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2012", is now available at Fast Market Research

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2012

Summary

Global Markets Direct's, 'Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2012', provides an overview of the Gastrointestinal Stromal Tumor (GIST) therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST). 'Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report

Details at
- www.fastmr.com/prod/330112_gastrointestinal_stromal_tumor_gist_p ..


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Gastrointestinal Stromal Tumor (GIST).
* A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Gastrointestinal Stromal Tumor (GIST) pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Gastrointestinal Stromal Tumor (GIST) therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gastrointestinal Stromal Tumor (GIST) Overview
Therapeutics Development
An Overview of Pipeline Products for Gastrointestinal Stromal Tumor (GIST)
Gastrointestinal Stromal Tumor (GIST) Therapeutics under Development by Companies
Gastrointestinal Stromal Tumor (GIST) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Products under Development by Companies
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Gastrointestinal Stromal Tumor (GIST) Therapeutics Development
Biogen Idec Inc.
Amgen Inc.
AstraZeneca PLC
Novartis AG
ImClone Systems Incorporated
SuperGen, Inc.
Bayer AG
Keryx Biopharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Ambit Biosciences Corporation
Deciphera Pharmaceuticals, LLC
AB Science
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Motesanib - Drug Profile
Regorafenib - Drug Profile
IMC-3G33 - Drug Profile
Recentin - Drug Profile
BIIB021 - Drug Profile
AT13387 - Drug Profile
Ganetespib - Drug Profile
AC220 - Drug Profile
Gleevec - Drug Profile
ARO-002 - Drug Profile
Yondelis - Drug Profile
Trabectedin - Drug Profile
Doxorubicin + Flavopiridol - Drug Profile
Regorafenib - Drug Profile
SU011248 - Drug Profile
Imatinib Mesylate - Drug Profile
Glivec - Drug Profile
Sorafenib - Drug Profile
FOLFOX + Bevacizumab - Drug Profile
Mixed Bacterial Vaccine - Drug Profile
Imatinib Mesylate - Drug Profile
Imatinib - Drug Profile
Dasatinib - Drug Profile
Glivec - Drug Profile
Perifosine + Imatinib Mesylate - Drug Profile
AB1010 - Drug Profile
Perifosine + Sunitinib Malate - Drug Profile
Brostallicin - Drug Profile
Gleevec - Drug Profile
AUY922 - Drug Profile
Glivec - Drug Profile
Gleevec - Drug Profile
Temsirolimus - Drug Profile
Bevacizumab + Capecitabine + Carboplatin - Drug Profile
DP-3407 - Drug Profile
DP-3429 - Drug Profile
Dasatinib - Drug Profile
Gleevec - Drug Profile
Bevacizumab + Imatinib mesylate - Drug Profile
Imatinib Mesylate + SU011248 - Drug Profile
Glivec - Drug Profile
Glivec - Drug Profile
TH-302 + Sunitinib - Drug Profile
Gleevec + Nilotinib - Drug Profile
GDC-0449 + RO4929097 - Drug Profile
Imatinib Mesylate - Drug Profile
Bevacizumab + Dasatinib - Drug Profile
Telomerase Peptide + GM-CSF - Drug Profile
Nilotinib + Imatinib - Drug Profile
Alemtuzumab + Cyclophosphamide + Doxorubicin Hydrochloride + Prednisolone + Vincristine Sulfate - Drug Profile
Bevacizumab + 5-fluorouracil + Leucovorin + Oxaliplatin - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=330112&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.